Paclitaxel

For research use only. Not for use in humans.

目录号:S1150 别名: NSC 125973, PTX, Taxol, Onxal 中文名称:紫杉醇

Paclitaxel Chemical Structure

CAS No. 33069-62-4

Paclitaxel (NSC 125973, PTX, Taxol, Onxal)是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 749.07 现货
RMB 571.49 现货
RMB 2235.46 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Paclitaxel发表文献192篇:

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述 Paclitaxel (NSC 125973, PTX, Taxol, Onxal)是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。
特性 Paclitaxel 是有丝分裂抑制剂。
靶点
Microtubule (human endothelial cells) [1]
0.1 pM
体外研究

Paclitaxel在104到 105倍更高浓度时,抑制非内皮性人类细胞,IC50 为1 nM -10 nM。Paclitaxel选择性抑制细胞增殖,具有种属特异性,在Paclitaxel极低浓度时,小鼠内皮细胞对 Paclitaxel不敏感。 极低浓度Paclitaxel抑制 人类内皮细胞,但是不影响细胞微管结构,且处理的细胞在 G2/M 期没有出现细胞周期停滞和凋亡,说明这是一种新型尚未查明的作用机制。在体外血管生成实验中,在三维纤维蛋白基质中,极低浓度Paclitaxel阻断人类内皮细胞形成芽管。[1] 在SMF存在时, Paclitaxel 作用于 K562 细胞的有效浓度从50 ng/ml降低到 10 ng/ml。在有或无SMF时,Paclitaxel 使K562 细胞周期停滞与DNA损伤相关。[2] Paclitaxel单独处理四种细胞系,包括A549 细胞,H358, H1395 细胞和H1666 细胞,抑制CDK1,这种作用存在时间依赖性。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XEPWlEPTB;MD6wNFAzQDdizszN MY\TRW5ITVJ?
LC-2-ad MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnXbItYUUN3ME2wMlAxODNzNzFOwG0> NE\sdG5USU6JRWK=
RL95-2 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nqdGlEPTB;MD6wNFA3PjhizszN M174fHNCVkeHUh?=
MZ1-PC NV7UXm9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHLSGpKSzVyPUCuNFAxPzJ7IN88US=> NInSbWFUSU6JRWK=
TE-8 NH7kNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPKTWM2OD1yLkCwNVE4KM7:TR?= M1jmR3NCVkeHUh?=
SW954 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jDU2lEPTB;MD6wNFEyQSEQvF2= NHTRcJlUSU6JRWK=
TE-11 NH3QR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnabHpKSzVyPUCuNFAyOjNizszN MnjNV2FPT0WU
PSN1 NEjRNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rDOmlEPTB;MD6wNFE{KM7:TR?= NF2xSVdUSU6JRWK=
MOLT-4 NUGzeldKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMECxOFkh|ryP NUXZPZJHW0GQR1XS
697 NUfNS2ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMECxOUDPxE1? NIWzN2hUSU6JRWK=
ETK-1 NHvDT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMECxOVIh|ryP MljDV2FPT0WU
TE-10 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rK[2lEPTB;MD6wNFE2PCEQvF2= MnnrV2FPT0WU
HUTU-80 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjCR|RmUUN3ME2wMlAxOTZ6IN88US=> MlHZV2FPT0WU
NTERA-S-cl-D1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrTTWM2OD1yLkCwNlA6KM7:TR?= NE[wbmhUSU6JRWK=
MFH-ino MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pv[mlEPTB;MD6wNFI3QCEQvF2= MXHTRW5ITVJ?
IA-LM Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH4TWM2OD1yLkCwNlgh|ryP NXPhPXFXW0GQR1XS
MC116 M4Dp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nLOmlEPTB;MD6wNFI5QSEQvF2= M2jJWHNCVkeHUh?=
RKO M2DiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonmTWM2OD1yLkCwNlk5KM7:TR?= M4XDfXNCVkeHUh?=
MRK-nu-1 NHf3NWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Pwd2lEPTB;MD6wNFI6QSEQvF2= M3TSXHNCVkeHUh?=
VA-ES-BJ MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\MT5RKSzVyPUCuNFA{KM7:TR?= MWfTRW5ITVJ?
KALS-1 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTVTWM2OD1yLkCwN|A5KM7:TR?= NH3j[21USU6JRWK=
BB30-HNC M3nhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLqeHNoUUN3ME2wMlAxOzF2IN88US=> M4PuVXNCVkeHUh?=
ACN M4fMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMECzNVYh|ryP M{mxbHNCVkeHUh?=
TE-9 M2roPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OzcWlEPTB;MD6wNFMzPiEQvF2= M4fNT3NCVkeHUh?=
SIG-M5 M2flbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G1fWlEPTB;MD6wNFMzPyEQvF2= NXfzTWFoW0GQR1XS
no-10 NIXuToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLTUmI3UUN3ME2wMlAxOzZ{IN88US=> NWTCUYh6W0GQR1XS
EW-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnLdpNKUUN3ME2wMlAxOzdzIN88US=> Mn\IV2FPT0WU
SK-LMS-1 NI\1W2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX6U2Z4UUN3ME2wMlAxPDBzIN88US=> MmTKV2FPT0WU
GT3TKB NVn4VoFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEC0N|Qh|ryP M3fndHNCVkeHUh?=
ES4 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEC0OFkh|ryP M2iyXXNCVkeHUh?=
IMR-5 NYTkW4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrLTWM2OD1yLkCwOFUh|ryP M{\KZXNCVkeHUh?=
NCI-H1648 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEC0Olkh|ryP NGDIVJdUSU6JRWK=
MV-4-11 M17COGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvWTWM2OD1yLkCwOFc2KM7:TR?= MV\TRW5ITVJ?
SK-UT-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEC0PEDPxE1? MoTSV2FPT0WU
NB13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELMOJdKSzVyPUCuNFA1QTFizszN M2X1c3NCVkeHUh?=
DJM-1 NUi5ToNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j0VWlEPTB;MD6wNFU{KM7:TR?= MkXvV2FPT0WU
ES8 M3\aUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rGbmlEPTB;MD6wNFU{QCEQvF2= NV3IdoE{W0GQR1XS
TE-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDyR3NKSzVyPUCuNFA2PyEQvF2= NWn5RnVmW0GQR1XS
KS-1 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LUcmlEPTB;MD6wNFU5OiEQvF2= NYTxd2IxW0GQR1XS
TE-1 M3S3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfKOHVKSzVyPUCuNFA3ODZizszN MX;TRW5ITVJ?
ATN-1 NWLBSpczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzneHNKSzVyPUCuNFA3ODlizszN NFLLNmFUSU6JRWK=
A4-Fuk NIL3dmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP6TWM2OD1yLkCwOlEyKM7:TR?= NXvxS3ZTW0GQR1XS
ALL-PO NHiyc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEC2N{DPxE1? MnzPV2FPT0WU
BE-13 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13IZWlEPTB;MD6wNFY{PiEQvF2= NUfEdY91W0GQR1XS
KM12 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEC2N|ch|ryP NGjwUY9USU6JRWK=
NOS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEC2OUDPxE1? M{Dx[XNCVkeHUh?=
SW962 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLnTWM2OD1yLkCwOlYzKM7:TR?= MWLTRW5ITVJ?
OCUB-M MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M133bmlEPTB;MD6wNFY3OiEQvF2= NFzqbFdUSU6JRWK=
NCI-H510A NH;DT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrTTWM2OD1yLkCwOlY2KM7:TR?= NHTnWHRUSU6JRWK=
EW-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXHO2RKSzVyPUCuNFA3QTRizszN MYrTRW5ITVJ?
KGN NV7lemlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[z[YlvUUN3ME2wMlAxPzF{IN88US=> MYTTRW5ITVJ?
LS-411N MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEC3NVch|ryP NVrMOZZMW0GQR1XS
Becker MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LDbmlEPTB;MD6wNFczKM7:TR?= MVzTRW5ITVJ?
HC-1 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT2WpRKSzVyPUCuNFA4OjFizszN MXLTRW5ITVJ?
CESS NG\TNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPxRpVKSzVyPUCuNFA4OzdizszN MVnTRW5ITVJ?
KURAMOCHI M1XmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn3Uo1KSzVyPUCuNFA4PDhizszN MkTWV2FPT0WU
TGBC24TKB M3y3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jiWGlEPTB;MD6wNFc2OiEQvF2= NYjtb2JiW0GQR1XS
SW982 NHTKNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfvfYNpUUN3ME2wMlAxPzZ4IN88US=> M4P2NHNCVkeHUh?=
HCE-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrTTWM2OD1yLkCwO|Y4KM7:TR?= NW\vVnB5W0GQR1XS
LOUCY MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEC3O|Uh|ryP M3\6WXNCVkeHUh?=
8-MG-BA MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDOTWM2OD1yLkCwO|k3KM7:TR?= NIPrUZRUSU6JRWK=
HT-144 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7BZnFKSzVyPUCuNFA5KM7:TR?= MlrsV2FPT0WU
LXF-289 M{XqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHnZnRKSzVyPUCuNFA5OThizszN M164OHNCVkeHUh?=
RS4-11 NFP0dGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETGfZpKSzVyPUCuNFA5OzZizszN MYXTRW5ITVJ?
DEL MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvqTWM2OD1yLkCwPFQ2KM7:TR?= MULTRW5ITVJ?
OCI-AML2 NV;iWoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvPW4tqUUN3ME2wMlAxQDV{IN88US=> NVLaT|J{W0GQR1XS
CCRF-CEM NGrhTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;sbpp6UUN3ME2wMlAxQDdzIN88US=> NFnIbJlUSU6JRWK=
A388 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PNUWlEPTB;MD6wNFg4PCEQvF2= MVXTRW5ITVJ?
KNS-42 M{LRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEC4PVEh|ryP M1[1VnNCVkeHUh?=
OVCAR-4 NYjr[GtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfmOpVKSzVyPUCuNFA6ODRizszN NXH6XGRzW0GQR1XS
NCI-H1355 NGO5bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPQT5JKSzVyPUCuNFA6OTRizszN Ml3TV2FPT0WU
BL-70 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHVcpZKSzVyPUCuNFA6OyEQvF2= NIK3N2tUSU6JRWK=
BL-41 NHXreGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEC5N|Qh|ryP NGm1R3lUSU6JRWK=
A101D M1HLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorsTWM2OD1yLkCwPVYh|ryP MmXZV2FPT0WU
HL-60 NGHhTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDMTWM2OD1yLkCwPVY3KM7:TR?= MXPTRW5ITVJ?
COR-L279 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITNR2xKSzVyPUCuNFA6QTlizszN M2\RZXNCVkeHUh?=
NCI-SNU-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i2ZWlEPTB;MD6wNVAxQCEQvF2= NYn5cYhtW0GQR1XS
Calu-6 M4C4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEGwNVIh|ryP NWP0R3REW0GQR1XS
SR M{PZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTWTWM2OD1yLkCxNFI3KM7:TR?= NVuzXmZKW0GQR1XS
QIMR-WIL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEGwN|Mh|ryP MoXkV2FPT0WU
LB647-SCLC M1zVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvQTWM2OD1yLkCxNFUyKM7:TR?= NWL3dZllW0GQR1XS
RPMI-8226 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnpTWM2OD1yLkCxNVAzKM7:TR?= M13HbHNCVkeHUh?=
SK-PN-DW MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Kw[WlEPTB;MD6wNVEyOiEQvF2= NX;zfIlPW0GQR1XS
SF268 NV2wdopNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEGxOVEh|ryP MWTTRW5ITVJ?
HD-MY-Z M1qxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn2TWM2OD1yLkCxNVY{KM7:TR?= NIX4OIJUSU6JRWK=
DOHH-2 NXO1R2g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLFTWM2OD1yLkCxNlA{KM7:TR?= NYnBNVNDW0GQR1XS
SCC-3 NXKyO403T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr0R5ZqUUN3ME2wMlAyOjB2IN88US=> Mlq5V2FPT0WU
ST486 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEGyNFQh|ryP NVvPWXlzW0GQR1XS
NALM-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvhTWM2OD1yLkCxNlE1KM7:TR?= NYTlZoRwW0GQR1XS
NCI-H1436 M3W4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfZTWM2OD1yLkCxNlMyKM7:TR?= MYTTRW5ITVJ?
KE-37 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEGyN|Qh|ryP NVrwfHNKW0GQR1XS
RPMI-8402 NV;XOY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLQRoRHUUN3ME2wMlAyOjV4IN88US=> M{WwSnNCVkeHUh?=
RXF393 M2PuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXCbVFrUUN3ME2wMlAyOjV5IN88US=> MkPqV2FPT0WU
KARPAS-45 M{XMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L2VGlEPTB;MD6wNVI4KM7:TR?= MYHTRW5ITVJ?
HOP-62 NGHZRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELqU|ZKSzVyPUCuNFEzPzZizszN M3vweHNCVkeHUh?=
ES1 NVHINWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEGyPFgh|ryP MoLzV2FPT0WU
L-363 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PqVWlEPTB;MD6wNVM2OSEQvF2= NXzXeoJxW0GQR1XS
GI-1 NWTnbXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvtNZRKSzVyPUCuNFE{PzNizszN M17XcnNCVkeHUh?=
CTV-1 NH\ae4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH1Z5NWUUN3ME2wMlAyPDd6IN88US=> NV7GZpZpW0GQR1XS
TE-5 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO5UYpKSzVyPUCuNFE1QTZizszN NEfhNlBUSU6JRWK=
SNU-C2B MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHmTWM2OD1yLkCxOFk3KM7:TR?= NXjDeYRFW0GQR1XS
K-562 M1zuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fXcWlEPTB;MD6wNVUyPiEQvF2= MU\TRW5ITVJ?
SNB75 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLDN2FKSzVyPUCuNFE2PCEQvF2= M3zwO3NCVkeHUh?=
MOLT-13 NHXYfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD1yLkCxOlM4KM7:TR?= MVTTRW5ITVJ?
LS-123 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z3OGlEPTB;MD6wNVY3PCEQvF2= NV;NU|VRW0GQR1XS
NCI-SNU-5 NWDUO|ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULD[WF3UUN3ME2wMlAyPzBzIN88US=> M4L2WXNCVkeHUh?=
Daudi M3vOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEG3NFgh|ryP M2HCTXNCVkeHUh?=
A253 NEXoVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jYVGlEPTB;MD6wNVc{QCEQvF2= M3LqcHNCVkeHUh?=
TGBC1TKB NFvOWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2foU2lEPTB;MD6wNVc2OiEQvF2= MVjTRW5ITVJ?
SJSA-1 M13V[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzQTXFKSzVyPUCuNFE4PjdizszN MYHTRW5ITVJ?
NCCIT M2LiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEG3Olkh|ryP NE[0WXpUSU6JRWK=
NCI-H69 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fTXWlEPTB;MD6wNVc4QCEQvF2= M2[wO3NCVkeHUh?=
SH-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMEG4PVUh|ryP NXHlfWZCW0GQR1XS
HCC1187 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpR3VMUUN3ME2wMlAyQTJ2IN88US=> MlHQV2FPT0WU
HCC1599 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O3eGlEPTB;MD6wNlAzKM7:TR?= M2L5fXNCVkeHUh?=
ONS-76 M2XDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluxTWM2OD1yLkCyNFM3KM7:TR?= NXuwRYFUW0GQR1XS
KU812 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLXTWM2OD1yLkCyNFM6KM7:TR?= MVzTRW5ITVJ?
ML-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEKwOFch|ryP NE\Gb2pUSU6JRWK=
HCE-T NWLSSXFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\Xb2lEPTB;MD6wNlA6OiEQvF2= NIX3XnVUSU6JRWK=
NCI-H446 NHjofGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEKxNVIh|ryP NEOwT3VUSU6JRWK=
RPMI-6666 M2mwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrSTWM2OD1yLkCyNVQ6KM7:TR?= M{XLUXNCVkeHUh?=
MOLT-16 NEPnUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7lWm1KSzVyPUCuNFIyPTNizszN M2PFcnNCVkeHUh?=
JiyoyeP-2003 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PSc2lEPTB;MD6wNlE4PiEQvF2= M{nqRnNCVkeHUh?=
MHH-PREB-1 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLIfmVzUUN3ME2wMlAzOTlzIN88US=> NEHlTGxUSU6JRWK=
MC-CAR NWLTUVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHaWHJKSzVyPUCuNFI{OjZizszN MlG4V2FPT0WU
BC-3 NGL0bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOzOGZKSzVyPUCuNFI{PDRizszN M2TTWnNCVkeHUh?=
KINGS-1 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjZXItKSzVyPUCuNFI{PTVizszN M3u5cnNCVkeHUh?=
PF-382 NFzGS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv4T4xkUUN3ME2wMlAzOzd6IN88US=> NFG3fpZUSU6JRWK=
J-RT3-T3-5 M4fkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;mVpFwUUN3ME2wMlAzOzh|IN88US=> NHPGcGZUSU6JRWK=
SF539 M4DSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M374PWlEPTB;MD6wNlQxOSEQvF2= NFTUOFdUSU6JRWK=
LB831-BLC M3W0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fkfGlEPTB;MD6wNlQ5PSEQvF2= M1z1N3NCVkeHUh?=
DMS-114 M4LQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXwTWM2OD1yLkCyOVAzKM7:TR?= M4HqVHNCVkeHUh?=
LB1047-RCC M3XoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e3cmlEPTB;MD6wNlUyKM7:TR?= MnvGV2FPT0WU
LB771-HNC NHzMc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEK1N|Qh|ryP NVnsZ3M{W0GQR1XS
BB65-RCC MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEK1N|Qh|ryP MkHrV2FPT0WU
BV-173 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXLNXZTUUN3ME2wMlAzPTV2IN88US=> MWTTRW5ITVJ?
ARH-77 NEfyR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGryNFZKSzVyPUCuNFI3ODFizszN M1WwOXNCVkeHUh?=
IST-MEL1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C1VWlEPTB;MD6wNlYzOyEQvF2= MX;TRW5ITVJ?
NB1 M1XEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqzTWM2OD1yLkCyOlg4KM7:TR?= MV7TRW5ITVJ?
EoL-1-cell MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rsPWlEPTB;MD6wNlY5QCEQvF2= NXjSXIkyW0GQR1XS
KY821 NWHueWNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvDUXlKSzVyPUCuNFI3QTdizszN MULTRW5ITVJ?
CMK NHPReZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PkOGlEPTB;MD6wNlc{PCEQvF2= M{C3RnNCVkeHUh?=
NCI-H2126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\PTWM2OD1yLkCyO|Y5KM7:TR?= NYrWbIk1W0GQR1XS
NCI-H526 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPNeG82UUN3ME2wMlAzQDlzIN88US=> M{G4W3NCVkeHUh?=
COLO-684 NFv4cVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorWTWM2OD1yLkCyPVA5KM7:TR?= NYH5W5NRW0GQR1XS
NCI-H747 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKwWWlKSzVyPUCuNFI6OzNizszN M{DYenNCVkeHUh?=
JAR M4C3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3HV3VuUUN3ME2wMlAzQTR4IN88US=> NX\EbZl[W0GQR1XS
MEG-01 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M130e2lEPTB;MD6wNlk4QCEQvF2= NXvvWZhKW0GQR1XS
MONO-MAC-6 NWrFe403T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEOwNlMh|ryP NWHuTYd{W0GQR1XS
IST-SL1 M{nQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X6N2lEPTB;MD6wN|A1OiEQvF2= M1nJbHNCVkeHUh?=
CPC-N Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMEOwO|kh|ryP NI\scGlUSU6JRWK=
NCI-H1963 M2n6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTrTWM2OD1yLkCzNVMyKM7:TR?= M4r3VnNCVkeHUh?=
K052 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3vTWM2OD1yLkCzNlQ4KM7:TR?= MYjTRW5ITVJ?
KM-H2 M3Pye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jKUGlEPTB;MD6wN|MxPyEQvF2= MXnTRW5ITVJ?
TE-12 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHXR|ZKSzVyPUCuNFM{ODlizszN MlvNV2FPT0WU
TK10 M{m5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH2TWM2OD1yLkCzN|U3KM7:TR?= Mmm5V2FPT0WU
NMC-G1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWzTWM2OD1yLkCzOFUzKM7:TR?= NWH2TpNPW0GQR1XS
no-11 NIX1SZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjCXFdKSzVyPUCuNFM1PzhizszN NYPiNY5mW0GQR1XS
NCI-H524 M1Kz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEO1Nlkh|ryP Moe0V2FPT0WU
MHH-CALL-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEO1OlIh|ryP MnfyV2FPT0WU
GB-1 NEjQeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDMVWNKSzVyPUCuNFM3KM7:TR?= NYOwdHM{W0GQR1XS
OPM-2 NGnJOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zLVWlEPTB;MD6wN|Y4OyEQvF2= Ml\FV2FPT0WU
RH-1 M{HONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fzcGlEPTB;MD6wN|gyQSEQvF2= M3qwcHNCVkeHUh?=
NCI-H64 NHjhVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEO4OVch|ryP NFHudIdUSU6JRWK=
EVSA-T MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEO5NlMh|ryP M2LifnNCVkeHUh?=
KARPAS-299 NVj6fplZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfZTWM2OD1yLkCzPVgh|ryP NHPuNFVUSU6JRWK=
MZ7-mel NGq1Z2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMESwOEDPxE1? M{PHZXNCVkeHUh?=
LB373-MEL-D NH7jPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq2TWM2OD1yLkC0NVA2KM7:TR?= NUnUd3JsW0GQR1XS
HEL M1fEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\TPJBKSzVyPUCuNFQyPCEQvF2= M4PMUXNCVkeHUh?=
SW872 M{Xmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGyTWM2OD1yLkC0NlEh|ryP NIjGNFRUSU6JRWK=
DU-4475 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj4[oVwUUN3ME2wMlA1OjR2IN88US=> M4fDO3NCVkeHUh?=
IST-SL2 NV3XZ2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofxTWM2OD1yLkC0Nlc2KM7:TR?= MYLTRW5ITVJ?
NCI-H82 NV3MNG81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzOZm9oUUN3ME2wMlA1OzB5IN88US=> M{D1UHNCVkeHUh?=
LC4-1 NGDjRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfKXpVmUUN3ME2wMlA1OzVzIN88US=> M3;SXXNCVkeHUh?=
HDLM-2 NXzO[2wyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTyTWM2OD1yLkC0N|kzKM7:TR?= MkX2V2FPT0WU
MMAC-SF NVzNV3cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrrPHRKSzVyPUCuNFQ2OzRizszN NHS2PHpUSU6JRWK=
L-540 M{j2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ifW1tUUN3ME2wMlA1PjN7IN88US=> MXHTRW5ITVJ?
MZ2-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLYTWM2OD1yLkC0O|QzKM7:TR?= NVL1O2ZNW0GQR1XS
LU-134-A MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\mZnhKSzVyPUCuNFQ4PzNizszN MYPTRW5ITVJ?
UACC-257 NFjPSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMES4OFkh|ryP MonKV2FPT0WU
NCI-H1581 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfKfmZKSzVyPUCuNFQ6PTNizszN M3jRWnNCVkeHUh?=
NB17 M4rH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0emlEPTB;MD6wOFk4QSEQvF2= NFvQV4VUSU6JRWK=
SBC-1 M4LwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\mS496UUN3ME2wMlA2ODR{IN88US=> NITDe5JUSU6JRWK=
TALL-1 NFLTNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDZSYhKSzVyPUCuNFUxPDVizszN NFXuWXZUSU6JRWK=
NCI-H1304 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDmXIJKSzVyPUCuNFUzODhizszN NF;rOW5USU6JRWK=
NEC8 NXv4fnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnizTWM2OD1yLkC1Nlg3KM7:TR?= NX\lbmt1W0GQR1XS
CAL-148 NESz[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXUTm91UUN3ME2wMlA2PDN7IN88US=> MmXtV2FPT0WU
CGTH-W-1 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnT[II{UUN3ME2wMlA2PDR7IN88US=> M4P2[nNCVkeHUh?=
NCI-H889 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3tT2RKSzVyPUCuNFU2QTJizszN NUDsOI4yW0GQR1XS
GR-ST M{fTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;WfmlEPTB;MD6wOVYzOSEQvF2= M1fERXNCVkeHUh?=
KARPAS-422 NX2zTWhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PHXWlEPTB;MD6wOVY2KM7:TR?= NVPXZ2hGW0GQR1XS
RPMI-8866 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne1TWM2OD1yLkC1O|EzKM7:TR?= M1e5OHNCVkeHUh?=
SCLC-21H NYPiN2JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnjTItKSzVyPUCuNFU5QDRizszN MnraV2FPT0WU
COR-L88 M{C0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGyTWM2OD1yLkC1PVI4KM7:TR?= NHvZRZhUSU6JRWK=
LU-139 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMEW5PFYh|ryP MnznV2FPT0WU
SF126 NES4O5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fX[WlEPTB;MD6wOlE{OyEQvF2= MXrTRW5ITVJ?
NCI-H1882 NGD2N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnqW2d{UUN3ME2wMlA3PDJ2IN88US=> M3nlXXNCVkeHUh?=
EW-24 NV3qXFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwME[0PFMh|ryP M1zmUnNCVkeHUh?=
CP67-MEL M4PHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe4e3FKSzVyPUCuNFY5OSEQvF2= M1PPcXNCVkeHUh?=
DG-75 NFXPUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHWTWM2OD1yLkC2PFk6KM7:TR?= NYHxWZhpW0GQR1XS
LOXIMVI NUnzcGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHJTWM2OD1yLkC3NFI5KM7:TR?= M{\DUHNCVkeHUh?=
HH MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvjTG1lUUN3ME2wMlA4OTV5IN88US=> NI\vbJZUSU6JRWK=
K5 NX3YPJpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jz[mlEPTB;MD6wO|IzPiEQvF2= NUfXeGxqW0GQR1XS
EC-GI-10 NWrtWGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrtXodKSzVyPUCuNFczPTdizszN MkPjV2FPT0WU
SK-N-DZ NGj2W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEezNFch|ryP NEnXbZVUSU6JRWK=
A3-KAW NXLyU4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHKNZVpUUN3ME2wMlA4OzVzIN88US=> NGW5cJJUSU6JRWK=
MLMA M{jqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEe0OlUh|ryP NIXxbYlUSU6JRWK=
LB996-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXmSWRCUUN3ME2wMlA4PzB5IN88US=> NEH6NolUSU6JRWK=
OS-RC-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TQNmlEPTB;MD6wO|c1QCEQvF2= MX7TRW5ITVJ?
CTB-1 M1PZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nzZmlEPTB;MD6wO|gyKM7:TR?= M2nSRnNCVkeHUh?=
IST-MES1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\2V2JrUUN3ME2wMlA4QTF{IN88US=> NIDZbo9USU6JRWK=
LS-1034 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEiwN|Uh|ryP NF\mfJhUSU6JRWK=
HT MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PncWlEPTB;MD6wPFA5PiEQvF2= M3:5S3NCVkeHUh?=
NCI-H2141 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm3b5VKSzVyPUCuNFgyKM7:TR?= M3TOOXNCVkeHUh?=
LB2518-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PxPWlEPTB;MD6wPFE1OSEQvF2= NUe3dW1MW0GQR1XS
GI-ME-N NWfFfIZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEi0OVIh|ryP NUKxOFF6W0GQR1XS
TGW MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEi2NFch|ryP NH\SU3FUSU6JRWK=
SK-NEP-1 M3TSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEi2OFEh|ryP MnPtV2FPT0WU
NOMO-1 NH:0dlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEmyO|Uh|ryP NV74XIlEW0GQR1XS
ES6 NXPOdlZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DoVmlEPTB;MD6wPVU5QSEQvF2= NE\OWHZUSU6JRWK=
NCI-H209 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG4NJFNUUN3ME2wMlA6Pzh4IN88US=> NHvZe4JUSU6JRWK=
GAK M2nL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC3ZnNKUUN3ME2wMlExOTZizszN MWnTRW5ITVJ?
BC-1 MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInzUm9KSzVyPUCuNVA{PjFizszN MoPsV2FPT0WU
KLE MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[0TmlEPTB;MD6xNFQ1OyEQvF2= Mo[wV2FPT0WU
EW-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmryTWM2OD1yLkGwPVgh|ryP MYnTRW5ITVJ?
NKM-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;kUnFKSzVyPUCuNVEyKM7:TR?= MWTTRW5ITVJ?
D-336MG MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSwTWM2OD1yLkGxNlQ1KM7:TR?= NH3ZWGtUSU6JRWK=
NB69 Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml72TWM2OD1yLkGxN|AyKM7:TR?= M2TBV3NCVkeHUh?=
D-263MG NVHKfYZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf6TWM2OD1yLkGxO|EzKM7:TR?= NUD0S2xIW0GQR1XS
KP-N-YS NEXEOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlThTWM2OD1yLkGyNlkyKM7:TR?= MoT2V2FPT0WU
NCI-H1155 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XpPWlEPTB;MD6xNlU2QCEQvF2= MX\TRW5ITVJ?
BOKU M3PITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMUK1O|kh|ryP M1\wbXNCVkeHUh?=
LAMA-84 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfZ[5VKSzVyPUCuNVI6QSEQvF2= M2L3SHNCVkeHUh?=
Raji MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\NO25OUUN3ME2wMlE{OTF5IN88US=> NV74cJB4W0GQR1XS
LU-65 M4DpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP2blNuUUN3ME2wMlE{OzB5IN88US=> MmTJV2FPT0WU
NCI-H187 NWGxeGtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnJTWM2OD1yLkGzPVI1KM7:TR?= MkfIV2FPT0WU
GCIY M1Xqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMUS5NFEh|ryP NE\YVoJUSU6JRWK=
NCI-H2107 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfFTWM2OD1yLkG1NFgh|ryP NXLIc2FsW0GQR1XS
NCI-H1522 M4D5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TTOmlEPTB;MD6xOVI3PiEQvF2= NVrjd5pRW0GQR1XS
NB6 NHrNZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMUW2NlMh|ryP MnTQV2FPT0WU
EM-2 NEfhUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nmb2lEPTB;MD6xOVcxPiEQvF2= M{e5OHNCVkeHUh?=
HCC2218 NXjlSJhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXVPJRKSzVyPUCuNVU6QCEQvF2= MWPTRW5ITVJ?
NCI-H748 M{DlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTJTWM2OD1yLkG2N|c3KM7:TR?= MlzSV2FPT0WU
MS-1 NWXMUlVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HNO2lEPTB;MD6xOlU{PyEQvF2= NWXKfJJvW0GQR1XS
NB5 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DEcmlEPTB;MD6xOlU6PyEQvF2= MkT2V2FPT0WU
OMC-1 NUO5WVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\vemN{UUN3ME2wMlE3Pjh6IN88US=> NIrLb2ZUSU6JRWK=
NCI-H345 M4LneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:4TWM2OD1yLkG2PVI5KM7:TR?= NFvGUY9USU6JRWK=
L-428 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnCTWM2OD1yLkG2PVQ2KM7:TR?= NHi0WWNUSU6JRWK=
SCH MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMUi2PFUh|ryP MVnTRW5ITVJ?
NCI-H1417 NIr5Wo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD5TWM2OD1yLkG5NlI4KM7:TR?= MWnTRW5ITVJ?
COLO-320-HSR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMUm1N|Ih|ryP NIK2c4VUSU6JRWK=
BT-474 NXziVoVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2zSpRKSzVyPUCuNlA5QTJizszN MkDMV2FPT0WU
GDM-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTDXVlKSzVyPUCuNlE6PzFizszN NELlT|BUSU6JRWK=
NCI-H2196 NYHUZ4RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHtSHdKSzVyPUCuNlIzOzVizszN M{DxXXNCVkeHUh?=
KP-N-RT-BM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMkKzOFkh|ryP NXzIV25DW0GQR1XS
KNS-81-FD NV\vTlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[yemlEPTB;MD6yNlk2QCEQvF2= NFuzSnBUSU6JRWK=
COLO-668 NH3weFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mxTWlEPTB;MD6yN|Y4PSEQvF2= NYjBTo0xW0GQR1XS
C2BBe1 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMk[3OFch|ryP MlTzV2FPT0WU
Ramos-2G6-4C10 M{\JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP1XIFuUUN3ME2wMlI3QTV2IN88US=> NXfrc3hoW0GQR1XS
CAS-1 M{HUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrOXZRrUUN3ME2wMlI4ODl4IN88US=> NYPwU5BpW0GQR1XS
GOTO NYHoT4J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMke4PVQh|ryP MoDUV2FPT0WU
LP-1 NEToOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnHOmxKSzVyPUCuNlgxPTdizszN MlPKV2FPT0WU
NCI-SNU-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PvR2lEPTB;MD6yPVQzOiEQvF2= M3\OdnNCVkeHUh?=
EB-3 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHVU4xwUUN3ME2wMlI6QTd7IN88US=> Mnz3V2FPT0WU
MHH-NB-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITBbZhKSzVyPUCuN|A1ODJizszN M3HDeXNCVkeHUh?=
SK-N-FI M3vwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\5fHhKSzVyPUCuN|E3QTJizszN M{TXeXNCVkeHUh?=
HCC2157 NEHVVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwM{O5NVMh|ryP NVzSS5JDW0GQR1XS
SIMA NWrxXIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LzWmlEPTB;MD6zOFU5OSEQvF2= NVfRR3U6W0GQR1XS
MDA-MB-134-VI NXfFcW96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7BS2VKSzVyPUCuN|Y6OjhizszN M{XMU3NCVkeHUh?=
NCI-H1694 NIC2T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf6TWM2OD1yLkO3JO69VQ>? M3;4UXNCVkeHUh?=
EHEB NFLxWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrRTWM2OD1yLkO5NFg2KM7:TR?= NWXTPWNDW0GQR1XS
U-266 NFrtcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX0TWM2OD1yLkO5PFQ3KM7:TR?= MYHTRW5ITVJ?
LC-1F MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeybVRKSzVyPUCuOFM4PjVizszN NVf0NZBSW0GQR1XS
SHP-77 NV\yOZJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr3fWJ4UUN3ME2wMlQ4QDV3IN88US=> M33DV3NCVkeHUh?=
LS-513 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXBeZZ7UUN3ME2wMlQ6OzB5IN88US=> NFXCN5FUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
体内研究

Paclitaxel单独处理 BC-V 和 BC-ER肿瘤的抑制定额分别为49.78 和 51.23%。20 mg/kg Paclitaxel处理6个周期,显著降低Ki-67阳性细胞百分比,BC-V肿瘤中降到20.4%,BC-ER 肿瘤中降到25.1%。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: 细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)
  • Concentrations: 0.1 pM-100 pM
  • Incubation Time: 72 小时
  • Method:

    培养细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)。在96孔板中使用6和12通道的细胞进行增殖。细胞按每孔3000–5000个细胞接种,然后粘附4小时。Paclitaxel在培养基中稀释,然后按一式四份加到孔中,细胞温育3天,然后加入MTS 试剂,然后定量测量每孔中的活细胞。


    (Only for Reference)
动物实验:

[4]

- 合并
  • Animal Models: 携带BC-V 和 BC-ER肿瘤的雌性20-22 g 纯和裸鼠
  • Dosages: 20 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 853.91
化学式

C47H51NO14

CAS号 33069-62-4
储存条件 粉状
溶于溶剂
别名 NSC 125973, PTX, Taxol, Onxal

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04252768 Not yet recruiting Drug: Eftilagimod Alpha|Drug: Paclitaxel Metastatic Breast Cancer Immutep S.A. June 2021 Phase 1
NCT04526470 Not yet recruiting Drug: Alpelisib + Paclitaxel Solid Tumor|Stomach Cancer Seoul National University Bundang Hospital September 1 2020 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 问题 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Tags: 购买Paclitaxel | Paclitaxel供应商 | 采购Paclitaxel | Paclitaxel价格 | Paclitaxel生产 | 订购Paclitaxel | Paclitaxel代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID